Ticagrelor for non-st elevated myocardial infarction

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 3 trial. Large late-stage trial in people. As of 19 Nov 2026, from 1 registered trial.

Why this status

  1. 22 Jan 2021: Trial registered, NCT04718025
  2. 7 Feb 2022: Trial started, NCT04718025

The trials

NCT04718025: Evaluation of Safety and Efficacy of Two Ticagrelor-based De-escalation Antiplatelet Strategies in Acute Coronary Syndrome

State
State not given
Phase
Phase 3
People
4,500 planned
Started
7 Feb 2022
Primary completion
30 Jun 2024
Arms
Low-dose ticagrelor with aspirin (LDTA), Low-dose ticagrelor with placebo (LDTP)
Results
None posted
Papers
doi:10.5603/cj.a2021.0056
  1. 22 Jan 2021: Trial registered
  2. 7 Feb 2022: Trial started

How the status changed

  1. 19 Nov 2026: First set: Phase 3 trial

About the treatment

Kind of treatment: Drug.

Also known as Brilinta, Brilique, Chewing Ticagrelor, Possia, Ticagrelor 180mg, Ticagrelor 45 mg, Ticagrelor 60mg, Ticagrelor 90mg, Ticagrelor 90mg for 6-month (immediately after PCI), Ticagrelor 90mg/60mg, Ticagrelor monotherapy, half-dose ticagrelor, low-dose ticagrelor.

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.